Analysts' ratings for Centene CNC over the last quarter vary from bullish to bearish, as provided by 10 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 7 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 4 | 1 | 0 | 0 |
| 2M Ago | 0 | 2 | 2 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $93.3, a high estimate of $110.00, and a low estimate of $82.00. Experiencing a 0.34% decline, the current average is now lower than the previous average price target of $93.62.
Breaking Down Analyst Ratings: A Detailed Examination
The perception of Centene by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Andrew Mok | Barclays | Raises | Overweight | $104.00 | $101.00 |
| George Hill | Deutsche Bank | Raises | Hold | $82.00 | $81.00 |
| Michael Wiederhorn | Oppenheimer | Maintains | Outperform | $110.00 | $110.00 |
| Stephen Baxter | Wells Fargo | Raises | Overweight | $93.00 | $89.00 |
| Stephen Baxter | Wells Fargo | Lowers | Overweight | $89.00 | $94.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $90.00 | - |
| Scott Fidel | Stephens & Co. | Lowers | Equal-Weight | $85.00 | $92.00 |
| Scott Fidel | Stephens & Co. | Lowers | Equal-Weight | $85.00 | $92.00 |
| Stephen Baxter | Wells Fargo | Raises | Overweight | $94.00 | $90.00 |
| Andrew Mok | Barclays | Announces | Overweight | $101.00 | - |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Centene. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Centene compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Centene's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Centene's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Centene analyst ratings.
Unveiling the Story Behind Centene
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of June 2023, mostly in Medicaid (67% of membership), the individual exchanges (14%), and Medicare Advantage (6%) plans. The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program.
Key Indicators: Centene's Financial Health
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Centene displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 3.9%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Centene's net margin is impressive, surpassing industry averages. With a net margin of 2.88%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.41%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Centene's ROA stands out, surpassing industry averages. With an impressive ROA of 1.39%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.67, caution is advised due to increased financial risk.
Understanding the Relevance of Analyst Ratings
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
